{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:54:04Z","timestamp":1791888844388,"version":"4.3.4"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.oooo.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T07:36:56Z","timestamp":1543822616000},"page":"289-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab\u2014a review"],"prefix":"10.1016","volume":"127","author":[{"given":"Rebecca","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-5619","authenticated-orcid":false,"given":"Vinod","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2018.11.012_bib0001","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0002","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the Jaw induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0004","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.oooo.2018.11.012_bib0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors\u2013a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.oooo.2018.11.012_bib0006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0007","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Experimentl Ther"},{"key":"10.1016\/j.oooo.2018.11.012_bib0008","unstructured":"NICE. NICE Evidence Search. Tyrosine kinase inhibitor. [online] Available at: www.evidence.nhs.uk\/Search?om=[%7B%22srn%22:[%22British%20National%20Formulary%20-%20BNF%22]%7D]&q=Tyrosine+kinase+inhibitor&sp=on. Accessed 28 May, 2018."},{"key":"10.1016\/j.oooo.2018.11.012_bib0009","unstructured":"National Cancer Institute. Angiogenesis Inhibitors. [online] Available at: www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/angiogenesis-inhibitors-fact-sheet. Accessed 28 May, 2018."},{"key":"10.1016\/j.oooo.2018.11.012_bib0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","article-title":"Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts","volume":"473","author":"Nakagawa","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.oooo.2018.11.012_bib0011","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0012","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5125\/jkaoms.2017.43.2.120","article-title":"A rare case of osteonecrosis of the jaw related to imatinib","volume":"43","author":"Viviano","year":"2017","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0013","first-page":"29","article-title":"Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib\u2014a case report with clinical implications","volume":"4","author":"Nicolatou-Galitis","year":"2013","journal-title":"Forum Clin Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw002","article-title":"Regorafenib also can cause osteonecrosis of the jaw","volume":"108","author":"Antonuzzo","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.oooo.2018.11.012_bib0015","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/adj.12254","article-title":"Osteonecrosis of the jaw in a patient receiving cabozantinib","volume":"60","author":"Marino","year":"2015","journal-title":"Aust Dent J"},{"key":"10.1016\/j.oooo.2018.11.012_bib0016","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/tcrm.2007.3.2.341","article-title":"Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)","volume":"3","author":"Le Tourneau","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.oooo.2018.11.012_bib0018","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib related osteonecrosis of jaw: a case report","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.11138\/jts\/2016.4.1.024","article-title":"Failed vascularized fibular graft in treatment of osteonecrosis of the femoral head. A histopathological analysis","volume":"4","author":"Meloni","year":"2016","journal-title":"Joints"},{"key":"10.1016\/j.oooo.2018.11.012_bib0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.oooo.2018.11.012_bib0022","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of 3 cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0023","unstructured":"NICE IMATINIB | Drug | BNF Provided by NICE [online] Bnf.nice.org.uk. Available at: Https:\/\/bnf.nice.org.uk\/drug\/imatinib.html. Accessed 28 May, 2018."},{"key":"10.1016\/j.oooo.2018.11.012_bib0024","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.oooo.2018.11.012_bib0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.2012.45.1294","article-title":"Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor","volume":"31","author":"Yeh","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0026","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: a review in hepatocellular carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0028","doi-asserted-by":"crossref","DOI":"10.5301\/tj.5000504","article-title":"Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma","volume":"102","author":"Garuti","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.oooo.2018.11.012_bib0029","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1200\/JCO.2009.23.4252","article-title":"Sorafenib-induced bilateral osteonecrosis of femoral heads","volume":"28","author":"Guillet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0030","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40265-015-0406-x","article-title":"Regorafenib: a review of its use in patients with advanced gastrointestinal stromal tumours","volume":"75","author":"Shirley","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.oooo.2018.11.012_bib0033","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.oooo.2017.08.003","article-title":"Axitinib-related osteonecrosis of the jaw","volume":"124","author":"Patel","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0034","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ctrv.2015.04.007","article-title":"Drug induced osteonecrosis of the jaw","volume":"41","author":"Issam","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.oooo.2018.11.012_bib0035","unstructured":"NICE PAZOPANIB | Drug | BNF Provided by NICE [online] Available at: Https:\/\/bnf.nice.org.uk\/drug\/pazopanib.html. Accessed 28 May, 2018."},{"key":"10.1016\/j.oooo.2018.11.012_bib0036","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omsc.2017.03.001","article-title":"Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient","volume":"3","author":"Jung","year":"2017","journal-title":"Oral Maxillofac Surg Cases"},{"key":"10.1016\/j.oooo.2018.11.012_bib0037","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40265-014-0265-x","article-title":"Cabozantinib: a review of its use in patients with medullary thyroid cancer","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.oooo.2018.11.012_bib0038","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s40265-016-0661-5","article-title":"Cabozantanib: a review in advanced renal cell carcinoma","volume":"76","author":"Al-Salama","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.oooo.2018.11.012_bib0039","series-title":"In: Organofluorine Compounds in Biology and Medicine","first-page":"265","article-title":"Organofluorine compounds as anti-cancer agents [Chapter 9]","author":"Prakash Reddy","year":"2015"},{"key":"10.1016\/j.oooo.2018.11.012_bib0041","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","article-title":"Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with anti-resorptives. A report of seven cases from the Copenhagen ONJ cohort","volume":"125","author":"Abel Mahedi Mohamed","year":"2018","journal-title":"Oral Surg, Oral Med, Oral Path and Oral Radiol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0042","first-page":"650","article-title":"Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations","volume":"63","author":"Coulson","year":"2014","journal-title":"West Indian Med J"},{"key":"10.1016\/j.oooo.2018.11.012_bib0043","unstructured":"American Cancer Society. Monoclonal antibodies to treat cancer | American Cancer Society. [online] Available at: Https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/treatment-types\/immunotherapy\/monoclonal-antibodies.html. Accessed 28 May, 2018."},{"key":"10.1016\/j.oooo.2018.11.012_bib0044","doi-asserted-by":"crossref","first-page":"e26333","DOI":"10.4161\/onci.26333","article-title":"Adverse events to monoclonal antibodies used for cancer therapy","volume":"2","author":"Baldo","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.oooo.2018.11.012_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8768162","article-title":"Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches","volume":"2016","author":"Lombard","year":"2016","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.oooo.2018.11.012_bib0047","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Santos-Silva","year":"2013","journal-title":"Oral Surg, Oral Med, Oral Path and Oral Radiol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0048","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.oooo.2018.11.012_bib0049","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/dj4040039","article-title":"Delayed diagnosis of osteonecrosis of the jaw (ONJ) associated with bevacizumab therapy in colorectal cancer patients: report of two cases","volume":"4","author":"Erovigni","year":"2016","journal-title":"Dent J (Basel)"},{"key":"10.1016\/j.oooo.2018.11.012_bib0051","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.oooo.2018.11.012_bib0052","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.joms.2011.02.104","article-title":"Osteonecrosis after administration of intravitreous bevacizumab","volume":"70","author":"Hopp","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0053","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.oooo.2018.11.012_bib0055","first-page":"123","article-title":"Anti-angiogenic effects of biotechnological therapies in rheumatic diseases","volume":"11","author":"Cantatore","year":"2017","journal-title":"Biologics"},{"key":"10.1016\/j.oooo.2018.11.012_bib0056","doi-asserted-by":"crossref","unstructured":"Weigart K, Lewgoy J, Mazzoleni DS, Franco FR, Lisandra E, Henrique Sasso J. Rituximab and osteonecrosis of the jaws: case study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:e188-e189.","DOI":"10.1016\/j.oooo.2013.12.203"},{"key":"10.1016\/j.oooo.2018.11.012_bib0057","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcms.2013.05.014","article-title":"Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab","volume":"42","author":"Allegra","year":"2014","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0058","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/j.joms.2017.05.016","article-title":"Osteonecrosis of the jaw in a patient presenting with post-transplantation lymphoproliferative disorder treated with rituximab: a case report","volume":"75","author":"Kerbin","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-14-6","article-title":"Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report","volume":"14","author":"Preidl","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0061","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2856926","article-title":"Adalimumab: another medication related to osteonecrosis of the jaws?","volume":"2016","author":"Cassoni","year":"2016","journal-title":"Case reports in dentistry"},{"key":"10.1016\/j.oooo.2018.11.012_bib0063","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.12659\/AJCR.905355","article-title":"A case of osteonecrosis of the jaw in a patient with Crohn's disease treated with infliximab","volume":"18","author":"Favia","year":"2017","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.oooo.2018.11.012_bib0064","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/rheumatology\/kes351","article-title":"Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy","volume":"52","author":"Ebker","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.oooo.2018.11.012_bib0065","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2018.11.012_bib0066","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2018.11.012_bib0067","doi-asserted-by":"crossref","unstructured":"Riggs P, La Vallie ER, McCoy JM. Introduction to expression by fusion protein vectors. Curr Protoc Mol Biol 2001. Chapter 16: Unit16.4A. http:\/\/doi.org\/10.1002\/0471142727.mb1604as28.","DOI":"10.1002\/0471142727.mb1604as28"},{"key":"10.1016\/j.oooo.2018.11.012_bib0068","unstructured":"Schmidt, SR. Fusion proteins: applications and challenges - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 2. [online] What-when-how.com. Available at: Http:\/\/what-when-how.com\/Tutorial\/topic-57rjoq\/Fusion-Protein-Technologies-for-Biopharmaceuticals-Applications-and-Challenges-28.html. Accessed 28 May, 2018."},{"key":"10.1016\/j.oooo.2018.11.012_bib0069","unstructured":"NICE AFLIBERCEPT | Drug | BNF Provided by NICE [online] Available at: Https:\/\/bnf.nice.org.uk\/drug\/aflibercept.html. Accessed 28 May, 2018."},{"key":"10.1016\/j.oooo.2018.11.012_bib0070","unstructured":"Ema.europa.eu. ZALTRAP Product Characteristics. [online] Available at: Http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002532\/WC500139484.pdf. Accessed 28 May, 2018."},{"key":"10.1016\/j.oooo.2018.11.012_bib0071","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejca.2013.09.013","article-title":"Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR)","volume":"50","author":"Tabernero","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.oooo.2018.11.012_bib0072","doi-asserted-by":"crossref","first-page":"81","DOI":"10.21037\/jgo.2016.05.07","article-title":"Osteonecrosis of the jaw associated with ziv-aflibercept","volume":"7","author":"Mawardi","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.oooo.2018.11.012_bib0073","article-title":"Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district","volume":"102","author":"Ponzetti","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.oooo.2018.11.012_bib0074","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bjoms.2016.11.315","article-title":"Medication-related osteonecrosis of the jaw associated with aflibercept","volume":"55","author":"Zarringhalam","year":"2017","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0076","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.9207.1","article-title":"mTOR inhibitors in cancer therapy","volume":"5","author":"Xie","year":"2016","journal-title":"F1000 Res"},{"key":"10.1016\/j.oooo.2018.11.012_bib0077","first-page":"15","article-title":"mTOR Inhibitors at a Glance","volume":"7","author":"Zheng","year":"2015","journal-title":"Mol Cell Pharmacol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0078","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bdj.2015.680","article-title":"New cancer therapies and jaw necrosis","volume":"219","author":"Patel","year":"2015","journal-title":"Br Dent J"},{"key":"10.1016\/j.oooo.2018.11.012_bib0079","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","article-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology","volume":"15","author":"Fusco","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.oooo.2018.11.012_bib0082","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bone.2004.07.013","article-title":"Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts","volume":"35","author":"Kneissel","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.oooo.2018.11.012_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23937\/2469-5734\/1510033","article-title":"Medication-related osteonecrosis of the jaw with the mTOR inhibitor Everolimus in a patient with estrogen-receptor positive breast cancer: a case report","volume":"2","author":"Lee","year":"2016","journal-title":"Int J Oral Dent Health"},{"key":"10.1016\/j.oooo.2018.11.012_bib0084","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3892\/mco.2016.1100","article-title":"Osteonecrosis of the jaw associated with everolimus: a case report","volume":"6","author":"Yamamoto","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0085","first-page":"20","article-title":"Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?","volume":"4","author":"Giancola","year":"2013","journal-title":"Ann Stomatol (Roma)"},{"key":"10.1016\/j.oooo.2018.11.012_bib0086","doi-asserted-by":"crossref","first-page":"E302","DOI":"10.1016\/j.bjoms.2013.09.008","article-title":"Osteonecrosis of the jaw related to everolimus: a case report","volume":"51","author":"Kim","year":"2013","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18875\/2375-7043.4.401","article-title":"Osteonecrosis of the Jaw in a patient treated with denosumab and temsirolimus","volume":"4","author":"Nifosi","year":"2017","journal-title":"SAJ Case Rep"},{"key":"10.1016\/j.oooo.2018.11.012_bib0088","first-page":"952","article-title":"Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports","volume":"16","author":"Agrillo","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.oooo.2018.11.012_bib0089","first-page":"258","article-title":"Radiopharmaceuticals for the palliation of painful bone metastases: a systematic review","volume":"75","author":"Baumann","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0090","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4329\/wjr.v6.i7.480","article-title":"Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters","volume":"6","author":"Wieder","year":"2014","journal-title":"World J Radiol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0093","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4184\/asj.2016.10.4.787","article-title":"Selective estrogen receptor modulators","volume":"10","author":"An","year":"2016","journal-title":"Asian Spine J"},{"key":"10.1016\/j.oooo.2018.11.012_bib0094","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3109\/13697137.2012.688079","article-title":"The evolution of selective estrogen receptor modulators in osteoporosis therapy","volume":"15","author":"Hadji","year":"2012","journal-title":"Climacteric"},{"issue":"5","key":"10.1016\/j.oooo.2018.11.012_bib0095","article-title":"Osteonecrosis of the jaw in a patient on raloxifene: a case report","volume":"46","author":"Baur","year":"2015","journal-title":"Quint Int"},{"key":"10.1016\/j.oooo.2018.11.012_bib0097","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1746-160X-8-26","article-title":"Short time administration of antirheumatic drugs\u2014methotrexate as a strong inhibitor of osteoblast's proliferation in vitro","volume":"8","author":"Annussek","year":"2012","journal-title":"Head Face Med"},{"key":"10.1016\/j.oooo.2018.11.012_bib0098","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/8756-3282(94)00032-U","article-title":"The short- and long-term effects of methotrexate on the rat skeleton","volume":"16","author":"Wheeler","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.oooo.2018.11.012_bib0099","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.joms.2016.07.019","article-title":"Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases","volume":"75","author":"Aghlaoo","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.11.012_bib0100","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.oooo.2017.09.005","article-title":"Methotrexate-associated osteonecrosis of the jaw: a report of two cases","volume":"124","author":"Henien","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0101","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa0903036","article-title":"Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells","volume":"362","author":"Greenberger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2018.11.012_bib0102","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1620\/tjem.217.51","article-title":"Glucocorticoid inhibits bone regeneration after osteonecrosis of the femoral head in aged female rats","volume":"217","author":"Takano-Murakami","year":"2009","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.oooo.2018.11.012_bib0103","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ecl.2012.04.004","article-title":"Glucocorticoid-induced osteoporosis and osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.oooo.2018.11.012_bib0104","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ajoms.2014.05.009","article-title":"Osteonecrosis of mandible: a rare complication of long-term steroid use","volume":"27","author":"Wong","year":"2015","journal-title":"J Oral Maxillofac Surg Med Pathol"},{"key":"10.1016\/j.oooo.2018.11.012_bib0105","first-page":"29","article-title":"Osteonecrosis of the jaws related to corticosteroids therapy: a case report","volume":"5","author":"Nisi","year":"2014","journal-title":"Ann Stomatol (Roma)"},{"key":"10.1016\/j.oooo.2018.11.012_bib0106","unstructured":"https:\/\/www.aaoms.org\/docs\/govt_affairs\/advocacy_white_papers\/mronj_position_paper.pdf."},{"key":"10.1016\/j.oooo.2018.11.012_bib0107","unstructured":"http:\/\/www.sdcep.org.uk\/wp-content\/uploads\/2017\/04\/SDCEP-Oral-Health-Management-of-Patients-at-Risk-of-MRONJ-Guidance-full.pdf."}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221244031831277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221244031831277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T14:28:59Z","timestamp":1605536939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221244031831277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S221244031831277X"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2018.11.012","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab\u2014a review","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}